Secor Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Secor Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,285	Closed	-$218K	–	579
2018 Q2	$218K	Buy	+1,285	New	+$199K	0.02%	448
2017 Q4	–	Sell	-4,554	Closed	-$674K	–	595
2017 Q3	$692K	Buy	4,554 +861	+23%	+$130K	0.07%	310
2017 Q2	$476K	Sell	3,693 -26,911	-88%	-$3.24M	0.04%	353
2017 Q1	$3.35M	Sell	30,604 -12,586	-29%	-$1.11M	0.37%	82
2016 Q4	$3.18M	Buy	43,190 +29,067	+206%	+$2.37M	0.39%	69
2016 Q3	$1.23M	Buy	+14,123	New	+$1.33M	0.13%	224
2016 Q2	–	Sell	-13,017	Closed	-$1.03M	–	718
2016 Q1	$1.03M	Buy	+13,017	New	+$1.18M	0.14%	152
2015 Q4	–	Sell	-2,365	Closed	-$246K	–	652
2015 Q3	$246K	Buy	+2,365	New	+$304K	0.08%	402

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Secor Capital Advisors's VRTX Position: Q3 2018 in Review

Secor Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 1,285 shares — an estimated $218K sold.

Secor Capital Advisors first reported a position in VRTX in Q3 2015 and held it in 8 quarters. The position peaked at $3.35M in Q1 2017. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Secor Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Secor Capital Advisors sold 1,285 Vertex Pharmaceuticals shares in Q3 2018, an estimated $218K.
Secor Capital Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Secor Capital Advisors's Vertex Pharmaceuticals position peaked at $3.35M in Q1 2017.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.